COPD: Journal of Chronic Obstructive Pulmonary Disease

PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market

Retrieved on: 
Thursday, February 4, 2021

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG Confirms $300,000 Sales Agreement with Cannabis Cultivation Subsidiary

Retrieved on: 
Wednesday, February 3, 2021

Sandusky, Ohio--(Newsfile Corp. - February 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a $300,000 sales agreement executed by the Company's cannabis cultivation subsidiary.

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - February 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a $300,000 sales agreement executed by the Company's cannabis cultivation subsidiary.
  • Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (OTC Pink: PURA).
  • The acquisition was made in conjunction with PAOG's overall strategy to refresh and renew its overall cannabis healthcare industry strategy.
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.

PAOG Confirms CBD Nutraceutical Development and Distribution Partners

Retrieved on: 
Tuesday, February 2, 2021

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG also plans to work with USMJ, in addition to other distribution channels, to distribute PAOG nutraceuticals through USJM's ecommerce site www.usjm.com .
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Blue Health Intelligence Data Report Finds Decline in Chronic Pulmonary Disease

Retrieved on: 
Tuesday, February 2, 2021

The report, " Using BHI Data to Uncover Improvement Opportunities in Chronic Obstructive Pulmonary Disease ," was conducted using BHI's National Data Repository,the most robust and conformed claims database in the nation.

Key Points: 
  • The report, " Using BHI Data to Uncover Improvement Opportunities in Chronic Obstructive Pulmonary Disease ," was conducted using BHI's National Data Repository,the most robust and conformed claims database in the nation.
  • The link to smoking as a leading cause of COPD appears in the state-by-state data contained in the BHI report.
  • Blue Health Intelligence (BHI) delivers insights that empower healthcare organizations toimprove care, reduce costs, and optimize performance.
  • BHI is an independent licensee of the Blue Cross Blue Shield Association and carries the trade name of Health Intelligence Company, LLC.

PAOG Takes Next Step To Produce Cannabis Nutraceuticals

Retrieved on: 
Wednesday, January 27, 2021

SANDUSKY, Ohio, Jan. 27, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced moving forward with its initiative to produce cannabis nutraceuticals.

Key Points: 
  • SANDUSKY, Ohio, Jan. 27, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced moving forward with its initiative to produce cannabis nutraceuticals.
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • Earlier this week PRCCI advanced next step plans to PAOG to advance the nutraceutical developments.
  • PAOG plans to work with Alkame Holdings, Inc. (USOTC: ALKM) in the packaging of its nutraceuticals.

New Treatment for Severe Emphysema Now Covered Under Highmark Blue Cross Blue Shield

Retrieved on: 
Monday, January 18, 2021

CENTER VALLEY, Pa., Jan. 18, 2021 /PRNewswire/ --Olympus announced that Highmark Blue Cross Blue Shield (BCBS) updated its coverage policy to include the Spiration Valve System for eligible patients suffering from severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • CENTER VALLEY, Pa., Jan. 18, 2021 /PRNewswire/ --Olympus announced that Highmark Blue Cross Blue Shield (BCBS) updated its coverage policy to include the Spiration Valve System for eligible patients suffering from severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD).
  • Highmark is a nationally recognized industry leader in developing up-to-date policy guidelines for safe and effective medical technologies.
  • It is an independent licensee of the Blue Cross and Blue Shield Association, and the fourth-largest overall Blue Cross Blue Shield-affiliated organization, with over 5 million members in Delaware, West Virginia, and Pennsylvania.
  • During the minimally invasive BLVRprocedure with the Spiration Valve System, umbrella-shaped endobronchial lung valves are positioned in selected airways.

PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals

Retrieved on: 
Thursday, January 14, 2021

SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ --PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year.

Key Points: 
  • SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ --PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year.
  • Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
  • OnJuly 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG is targeting revenue in 2021 resulting from its nutraceutical developments.

PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

Retrieved on: 
Thursday, January 14, 2021

Sandusky, Ohio--(Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year.

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year.
  • Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
  • On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG has also entered into a strategic partnership with PURA in conjunction with PURA's overall initiative in Farmersville, Texas.

PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Retrieved on: 
Tuesday, January 12, 2021

Sandusky, Ohio--(Newsfile Corp. - January 12, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021.

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - January 12, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021.
  • In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2020

Retrieved on: 
Monday, January 11, 2021

Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2020.

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2020.
  • In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.